Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours

This publication has 23 references indexed in Scilit:

• Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II)
  Gynecologic Oncology, 1992
• Growth‐inhibitory effect of quercetin and presence of type‐II estrogen‐binding sites in human colon‐cancer cell lines and primary colorectal tumors
  International Journal of Cancer, 1992
• Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites
  Cancer Chemotherapy and Pharmacology, 1991
• Type‐II estrogen binding sites in a lymphoblastoid cell line and growth‐inhibitory effect of estrogen, anti‐estrogen and bioflavonoids
  International Journal of Cancer, 1990
• Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells
  British Journal of Cancer, 1990
• Type II oestrogen binding sites in human colorectal carcinoma.
  Journal of Clinical Pathology, 1990
• Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth
  Anti-Cancer Drugs, 1990
• Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids
  British Journal of Haematology, 1990
• Type II Estrogen-Binding Sites and 17β-Hydroxysteroid Dehydrogenase Activity in Human Peripheral Blood Mononuclear Cells*
  Journal of Clinical Endocrinology & Metabolism, 1988
• Two Binding Sites for Estradiol in Rat Uterine Nuclei: Relationship to Uterotropic Response*
  Endocrinology, 1979